Literature DB >> 3192772

The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia.

W Futterweit1, A Dunaif, H C Yeh, P Kingsley.   

Abstract

Endocrine dysfunction was studied in 109 consecutive female patients with moderate to severe alopecia, mostly of a diffuse pattern. The study included an evaluation of associated hirsutism and/or menstrual dysfunction, plasma hormonal measurements, and ultrasonography of the ovaries. A control group of 24 ovulatory, nonhirsute, nonalopecia individuals was also studied. Of the 109 patients, 70 (64.2%) had no clinical evidence of hirsutism or menstrual dysfunction. Two of 44 patients tested with cosyntropin (Cortrosyn) had 21-hydroxylase deficiency, whereas two other patients had hyperprolactinemia caused by pituitary tumors. Hyperandrogenism was defined as an increase in any of the plasma androgens (testosterone, non-sex hormone-binding globulin bound testosterone, dehydroepiandrosterone sulfate, androstenedione, or dihydrotestosterone) and was noted in 42 of the 109 patients studied (38.5%). Of these 42 patients, 11 were ovulatory with no evidence of clinical hirsutism, 13 were ovulatory and hirsute, and 18 had oligomenorrhea or amenorrhea with or without hirsutism with confirmatory evidence of polycystic ovarian disease. Patients with diffuse alopecia may demonstrate hyperandrogenism, even in the absence of hirsutism, oligomenorrhea, or amenorrhea. The most common endocrine disorder in this series of patients with diffuse alopecia was polycystic ovarian disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192772     DOI: 10.1016/s0190-9622(88)70241-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  20 in total

Review 1.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

Review 2.  Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome.

Authors:  Ana Teresa Brinca; Ana Cristina Ramalhinho; Ângela Sousa; António Hélio Oliani; Luiza Breitenfeld; Luís A Passarinha; Eugenia Gallardo
Journal:  Biomedicines       Date:  2022-05-27

Review 3.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

4.  Evaluation of dry eye and Meibomian gland dysfunction in female androgenetic alopecia patients.

Authors:  Pelin Kiyat; Melis Palamar; Bengu Gerceker Turk; Ayse Yagci
Journal:  Int Ophthalmol       Date:  2021-07-09       Impact factor: 2.031

5.  Hair loss and hyperprolactinemia in women.

Authors:  Gerhard Lutz
Journal:  Dermatoendocrinol       Date:  2012-01-01

6.  Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study.

Authors:  R L Glaser; C Dimitrakakis; A G Messenger
Journal:  Br J Dermatol       Date:  2012-01-09       Impact factor: 9.302

Review 7.  The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms.

Authors:  R Dumitrescu; C Mehedintu; I Briceag; V L Purcarea; D Hudita
Journal:  J Med Life       Date:  2015 Apr-Jun

Review 8.  Female pattern hair loss: current treatment concepts.

Authors:  Quan Q Dinh; Rodney Sinclair
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

9.  Androgenetic Alopecia in a Patient with Klinefelter Syndrome: Case Report and Literature Review.

Authors:  Waleed Alsalhi; Antonella Tosti
Journal:  Skin Appendage Disord       Date:  2020-12-07

Review 10.  Female pattern alopecia: current perspectives.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Int J Womens Health       Date:  2013-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.